Last reviewed 2026-05-13 · How we verify

Hillchol vaccine

Hillchol is a therapeutic vaccine designed to induce immune responses against cholesterol and lipid-related antigens to reduce cardiovascular risk.

Hillchol is a therapeutic vaccine designed to induce immune responses against cholesterol and lipid-related antigens to reduce cardiovascular risk. Used for Cardiovascular disease prevention / atherosclerosis risk reduction.

At a glance

Mechanism of action

The vaccine targets cholesterol metabolism and atherosclerosis-related pathways by stimulating the immune system to recognize and respond to lipid antigens. This approach aims to modulate immune tolerance to self-antigens involved in atherosclerosis progression and reduce cardiovascular events in at-risk populations.

Approved indications

• Cardiovascular disease prevention / atherosclerosis risk reduction

Common side effects

• Injection site reactions
• Fever
• Myalgia

Key clinical trials

• To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131) (PHASE3)
• A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131). (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Hillchol vaccine CI brief — competitive landscape report
• Hillchol vaccine updates RSS · CI watch RSS
• Bharat Biotech International Limited portfolio CI